Gaius Papirius Carbo Arvina

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023

NEW HAVEN, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Research and Development Expenses: Research and development expenses were $85.9 million for the quarter ended September 30, 2023, as compared with $77.5 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: General and administrative expenses were $22.6 million for the quarter ended September 30, 2023, as compared with $20.0 million for the quarter ended September 30, 2022.
  • Revenues: Revenues were $34.6 million for the quarter ended September 30, 2023, as compared with $33.2 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $64.0 million for the quarter ended September 30, 2023, as compared with $66.2 million for the quarter ended September 30, 2022.

Arvinas to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, November 2, 2023

Sean Cassidy, chief financial officer, and Ron Peck, M.D., chief medical officer will be available to participate in one-on-one meetings.

Key Points: 
  • Sean Cassidy, chief financial officer, and Ron Peck, M.D., chief medical officer will be available to participate in one-on-one meetings.
  • John Houston, Ph.D., chairperson, chief executive officer, and president, and Ron Peck, M.D., chief medical officer, will be available to participate in one-on-one meetings and will participate in a fireside chat.
  • John Houston, Ph.D., chairperson, chief executive officer, and president, and Sean Cassidy, chief financial officer will be available to participate in one-on-one meetings.
  • Ron Peck, M.D., chief medical officer and Jeff Boyle, vice president, investor relations, will be available to participate in one-on-one meetings and will participate in a fireside chat.

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

Retrieved on: 
Sunday, October 22, 2023

NEW HAVEN, Conn., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the presentation of interim data from the Company’s Phase 1/2 clinical trial for bavdegalutamide (ARV-110), a novel PROTAC® protein degrader targeting the androgen receptor (AR), in a poster session at the European Society for Medical Oncology Congress being held in Madrid from October 20 – 24, 2023. The Company will host a conference call to discuss these data and present new data from an updated analysis of its ongoing Phase 1/2 clinical trial with its second-generation PROTAC AR degrader, ARV-766, showing clinical activity extending across patients harboring tumors with AR LBD mutations and a tolerability profile that is superior to bavdegalutamide.

Key Points: 
  • AR L702H is a common AR ligand-binding domain (LBD) mutation that is not potently degraded by bavdegalutamide.
  • In patients with tumors harboring any AR LBD mutation except L702H alone, bavdegalutamide showed an rPFS of 8.2 months.
  • Our second generation PROTAC AR degrader, ARV-766, has demonstrated a broader efficacy profile and even better tolerability compared to bavdegalutamide in clinical settings.
  • ARV-766 was designed to improve upon the degradation profile of bavdegalutamide by also degrading AR L702H.

Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day

Retrieved on: 
Wednesday, October 18, 2023

NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company’s second annual “Arvinas Impact Day,” a company-wide community service day benefiting organizations in the Greater New Haven area.

Key Points: 
  • NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company’s second annual “Arvinas Impact Day,” a company-wide community service day benefiting organizations in the Greater New Haven area.
  • "'Arvinas Impact Day' is a reflection of our company's unwavering dedication to community.
  • Eight Arvinas volunteers prepared meals to be served to members of the Greater New Haven community.
  • Boys & Girls Club of Greater New Haven: Over 20 members of Arvinas worked to enhance indoor and outdoor facilities.

Arvinas to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, September 1, 2023

NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:

Key Points: 
  • NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
    Wells Fargo 2023 Healthcare Conference on Wednesday, September 6.
  • Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat.
  • Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat.
  • Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat.

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 8, 2023

NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • We are also on track to initiate a Phase 3 trial with bavdegalutamide in the second half of the year.
  • Research and Development Expenses: Research and development expenses were $103.4 million for the quarter ended June 30, 2023, as compared with $75.3 million for the quarter ended June 30, 2022.
  • Revenues: Revenues were $54.5 million for the quarter ended June 30, 2023 as compared with $33.8 million for the quarter ended June 30, 2022.
  • Net Loss: Net loss was $66.6 million for the quarter ended June 30, 2023, as compared with $70.0 million for the quarter ended June 30, 2022.

Arvinas Announces Changes to its Board of Directors

Retrieved on: 
Thursday, June 15, 2023

Additionally, Sunil Agarwal, M.D., has been appointed to join the company’s Board and Briggs Morrison, M.D., has been appointed Lead Independent Director of the Board.

Key Points: 
  • Additionally, Sunil Agarwal, M.D., has been appointed to join the company’s Board and Briggs Morrison, M.D., has been appointed Lead Independent Director of the Board.
  • “I have had the privilege of serving on Arvinas’ Board for the past decade and feel great pride for all that the company has accomplished during this time,” said Dr. Shannon.
  • “I am pleased to welcome Sunil to Arvinas’ Board of Directors,” said Dr. Houston.
  • “I look forward to contributing to Arvinas’ continued success, especially as the company plans and prepares to bring potential treatments to market.”

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations

Retrieved on: 
Thursday, June 8, 2023

NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced promising interim data from the Company’s Phase 1/2 dose escalation and expansion trial of ARV-766 in men with metastatic castration-resistant prostate cancer (mCRPC). ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR), including L702H, a mutation associated with resistance to abiraterone and other AR-pathway novel hormonal agents (NHA). The company will provide an overview of these data during a fireside chat at the Jefferies Healthcare Conference today, June 8, 2023, at 11 a.m. ET, which will be available to view in the Investors and Media section of the Arvinas website.

Key Points: 
  • The company will provide an overview of these data during a fireside chat at the Jefferies Healthcare Conference today, June 8, 2023, at 11 a.m.
  • ET, which will be available to view in the Investors and Media section of the Arvinas website .
  • “It’s very exciting to see ARV-766 show signs of efficacy in these late-line patients, including in patients with L702H mutations.
  • “These data increase our confidence in our ability to bring innovative treatment options to a patient population with significant unmet need.

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, May 5, 2023

NEW HAVEN, Conn., May 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • “We made substantial progress throughout the first quarter across all areas of our early- and late-stage pipeline,” said John Houston, Ph.D., president and chief executive officer at Arvinas.
  • Data are expected to be presented at a medical conference in the second half of 2023.
  • Revenues: Revenues were $32.5 million for the quarter ended March 31, 2023, as compared with $26.5 million for the quarter ended March 31, 2022.
  • Net Loss: Net loss was $81.9 million for the quarter ended March 31, 2023, as compared with $63.4 million for the quarter ended March 31, 2022.

Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference

Retrieved on: 
Wednesday, May 3, 2023

NEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Tuesday, May 9 at 6:40 p.m. ET/3:40 p.m. PT in Las Vegas.

Key Points: 
  • NEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Tuesday, May 9 at 6:40 p.m. ET/3:40 p.m. PT in Las Vegas.
  • A live audio webcast of the presentation will be available here and under “Events and Presentations” of the Investors and Media section of the Company’s website.